Skip to Main content Skip to Navigation
Journal articles

Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction.

Abstract : INTRODUCTION: In the literature, data on the effect of renal impairment on the pharmacokinetics of anticancer drugs are scarce. Here, we report a 68-year-old metastatic osteosarcoma patient with impaired renal function due to prior chemotherapy, who was treated on compassionate use basis with 400 mg/m(2) cetuximab. MATERIAL AND METHODS: Pharmacokinetic parameters after the first dose, including dose-normalised AUC from time zero to day 7, clearance, elimination half-life (t 1/2), were estimated using trapezoidal non-compartmental methods and compared to pharmacokinetic data from a study population with normal kidney function. RESULTS: The results showed that the pharmacokinetics of cetuximab in this patient with renal failure was similar to that with adequate renal function. CONCLUSION: This study suggests that cetuximab can be safely used in cancer patients with renal impairment without dose adjustment.
Complete list of metadata

Cited literature [2 references]  Display  Hide  Download
Contributor : Gilles Paintaud Connect in order to contact the contributor
Submitted on : Friday, May 16, 2014 - 11:27:01 AM
Last modification on : Monday, February 21, 2022 - 3:10:03 PM
Long-term archiving on: : Saturday, August 16, 2014 - 11:46:32 AM


Files produced by the author(s)




L. L. Krens, J. M. Baas, M. C. Verboom, G. Paintaud, C. Desvignes, et al.. Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction.. Cancer Chemotherapy and Pharmacology, Springer Verlag, 2014, epub ahead of print. ⟨10.1007/s00280-014-2462-4⟩. ⟨hal-00992023⟩



Record views


Files downloads